Last updated on July 2018

A Dose Frequency Optimization Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks


Brief description of study

The primary objective of this study is to show that PFS (progress-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks is non-inferior to nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).

Clinical Study Identifier: NCT02713867

Contact Investigators or Research Sites near you

Start Over

Enrique Perez, Site 0025

Texas Oncology, P.A.
Flower Mound, TX United States
2.09miles

Sharad Jain, Site 0016

Texas Oncology, P.A.
Denton, TX United States
8.97miles